Document Detail

Elevated serum D dimer: a degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction.
MedLine Citation:
PMID:  3711489     Owner:  NLM     Status:  MEDLINE    
D dimer, a degradation product of cross-linked fibrin, is generated by lysis of fibrin but not by lysis of fibrinogen and can be reliably detected by specific monoclonal antibody techniques. The generation of D dimer after intravenous streptokinase in acute myocardial infarction was studied with the use of a semiquantitative latex agglutination immunoassay. This assay utilizes the monoclonal antibody DD-3B6/22, raised by conventional hybridoma technology, against a highly purified preparation of human D dimer and is adjusted to give a positive agglutination at a D dimer serum concentration of greater than 200 ng/ml (upper limit of normal). Twenty-one patients with acute transmural myocardial infarction of less than 3 hours' duration were studied. Fifteen patients received 0.75 to 1.5 million U intravenous streptokinase and 6 patients were treated conventionally without thrombolytic therapy. An elevated serum level of D dimer was detected before treatment in only 1 of 15 patients receiving intravenous streptokinase and within 2 hours of treatment in the remaining 14 patients who received streptokinase. In contrast, an elevated serum D dimer level was not detected during the first 24 hours in any of the six conventionally treated patients, including two patients who manifested the clinical syndrome of spontaneous reperfusion. The data suggest that in patients with acute myocardial infarction, an elevated serum level of D dimer, a cross-linked fibrin degradation product occurs early after administration of a large dose of streptokinase, but is infrequent during the first 24 hours in conventionally treated patients with acute infarction. Measurement of D dimer may be potentially useful for monitoring thrombolysis in patients with acute myocardial infarction.
A S Lew; L Berberian; B Cercek; S Lee; P K Shah; W Ganz
Related Documents :
2195859 - Magnesium replacement therapy.
1746449 - Importance of the pharmacological profile of thrombolytic agents in clinical practice.
3914879 - Failure of intravenous pindolol to reduce the hemodynamic determinants of myocardial ox...
2182239 - Summary of u.s. clinical trials program for evaluation of anistreplase.
8857989 - Magnesium in cardioplegia: is it necessary?
8694669 - Admission serum magnesium level does not predict the hospital outcome of patients with ...
1267859 - Adrenocortical suppression and myocardial infarction in non-arteriosclerotic (virgin) a...
3115099 - Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction.
20559719 - Arrhythmias and vagus nerve stimulation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  7     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1986 Jun 
Date Detail:
Created Date:  1986-07-03     Completed Date:  1986-07-03     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1320-4     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fibrin Fibrinogen Degradation Products / analysis*
Injections, Intravenous
Latex Fixation Tests
Middle Aged
Myocardial Infarction / drug therapy*
Streptokinase / administration & dosage,  therapeutic use*
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/fibrin fragment D; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intertest variability of echocardiographic and chest X-ray measurements: implications for decision m...
Next Document:  The natural history of regional wall motion in the acutely infarcted canine ventricle.